undamentalytics Newsletter
Sign in

Merck & Co. revenue

Merck & Co.'s revenue was $65.01bn in fiscal 2025, up 1.3% on the year before. Since fiscal 2007 ($24.20bn) it has grown at a compound 7.9% a year. Over the last twelve months it was $66.57bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2007Dec 20072008Dec 20082009Dec 20092010Dec 20102016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue24.223.927.446.039.840.142.339.141.548.759.360.164.265.066.6
Growth on the year before—−1.4%+15.0%+67.7%−13.4%+0.8%+5.4%−7.5%+6.1%+17.3%+21.7%+1.4%+6.7%+1.3%—
Gross profit————25.827.228.827.127.935.141.944.049.048.648.6
Gross margin————64.8%67.8%68.1%69.3%67.2%72.0%70.6%73.2%76.3%74.8%73.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue YoY
United States $36.5B ▲ 13.1%
Outside the US $28.5B ▼ 10.6%
EMEA $14.6B ▲ 3.8%
Latin America $3.4B ▼ 1.4%
Asia Pacific $3B ▼ 2.5%
Other Countries $2.9B ▲ 12.5%
Japan $2.7B ▼ 17.3%
China $1.9B ▼ 64.7%

These categories overlap or exclude eliminations, so shares aren't shown.

From Merck & Co.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Merck & Co. $66.57bn 4.6% 4.5%
Pfizer $63.70bn -0.2% -7.0%
Astrazeneca PLC $58.74bn 8.6% —
Lilly (Eli) $86.46bn 45.5% 39.2%
Bristol Myers Squibb $50.03bn 4.2% 3.6%
Novo Nordisk A S $46.82bn 11.1% —

Compare with peers

Head to head: MRK vs PFEAZN vs MRKLLY vs MRK

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Merck & Co.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Merck & Co.